Invivo Therapeutics is a research and clinical-stage biomaterials and biotechnology company that focuses on the treatment of spinal cord injuries. Invivo Therapeutics earned the David S. Apple Award from the American Spinal Injury Association for its immense contribution to spinal cord injury medicine. The company’s investigational Neuro-Spinal Scaffold won the 2015 Becker’s Healthcare Spine Device Award.
InVivo is focused on redefining the treatment of spinal cord injury. By modulating the healing environment to facilitate cell survival and growth, it has the opportunity to change the treatment of spinal cord injury.
Following acute spinal cord injury, surgical implantation of the biodegradable Neuro-Spinal Scaffold within the decompressed and debrided injury epicenter is intended to support appositional healing, thereby reducing post-traumatic cavity formation, sparing white matter, and allowing neural regeneration across the healed wound epicenter.
Its Neuro-Spinal Scaffold, an investigational device, has received a Humanitarian Use Device (HUD) designation and it is currently being evaluated in the INSPIRE pivotal probable benefit study for the treatment of patients with complete (AIS A) traumatic acute spinal cord injury.